Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Clemizole · EPX-100, AL-20

Small molecule · developed by Epygenix

Phase 3 Most advanced trial
2 Registered trials

What is Clemizole?

Clemizole HCl is an orally administered agent studied in Lennox-Gastaut syndrome, a severe epilepsy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
EPX-100, AL-20, NSC-759290
Drug type
Small molecule
Therapy area
Neurology
Developer
Epygenix
In trials of
HRMY
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
85W6I13D8M

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05066217 Phase 3 Lennox Gastaut Syndrome Recruiting HRMY
NCT07879170 Phase 1 Healthy Participants Recruiting HRMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy ParticipantsLennox Gastaut Syndrome

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.